Latest News:

See the Health Watch feature on the BiovaxID Personalized Cancer Vaccine for Non-Hodgkin's Lymphoma

AutovaxID instruments featured in February 2007 Issue of Pharmaceutical Manufacturing: See article on p. 29 entitled "Vaccine Manufacturing Reborn"

Biovest International develops personalized immunotherapies for life threatening cancers of the blood system. Biovest is the holder of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute for the commercialization of BiovaxID, a personalized biologic therapeutic cancer vaccine for the treatment of non-Hodgkin’s lymphoma. This therapy, referred to as BiovaxID, is currently in a phase 3 pivotal trial at 24 major medical institutions in the US.

Biovest has a long history of manufacturing biological drugs from small research scale quantities to large volumes for Phase 1 and Phase 2 clinical material.  In addition, Biovest International develops, manufactures, and markets patented cell culture systems and equipment, including the innovative AutovaxID instruments, to pharmaceutical, diagnostic and biotechnology companies, as well as leading research institutions worldwide.